% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kotecha:1052252,
      author       = {Kotecha, Rupesh and Akdemir, Eyub Y and Kutuk, Tugce and
                      Ilgın, Can and Ahluwalia, Manmeet S and Bi, Wenya L and
                      Blakeley, Jaishri and Dixit, Karan S and Dunn, Ian F and
                      Galanis, Evanthia and Galldiks, Norbert and Huang, Raymond Y
                      and Johnson, Derek R and Kaley, Thomas J and Kamson, David O
                      and Kurz, Sylvia C and McDermott, Michael W and Odia, Yazmin
                      and Preusser, Matthias and Raizer, Jeffrey and Reardon,
                      David A and Rogers, C Leland and Ruda, Roberta and Schiff,
                      David and Vogelbaum, Michael A and Weller, Michael and Wen,
                      Patrick Y and Mehta, Minesh P},
      title        = {{B}enchmarking the efficacy of salvage systemic therapies
                      for recurrent meningioma: {A} {RANO} group systematic review
                      and meta-analysis to guide clinical trial design},
      journal      = {Neuro-Oncology},
      volume       = {27},
      number       = {7},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2026-00869},
      pages        = {1670 - 1685},
      year         = {2025},
      note         = {Neuro Oncol . 2025 Sep 8;27(7):1670-1685.Funding: none
                      declared},
      abstract     = {Background. Despite advances in our understanding of the
                      molecular underpinnings of meningioma progressionand
                      innovations in systemic and local treatments, recurrent
                      meningiomas remain a substantial therapeutic challenge.The
                      objective of this systematic review and meta-analysis is to
                      provide a historical baseline, contemporaryanalysis, and
                      propose a “rate of probable interest” to inform future
                      clinical trial design and development on behalfof the
                      Response Assessment in Neuro-Oncology meningioma
                      group.Methods. PubMed, ClinicalTrials.gov, and ASCOpubs
                      databases were screened for clinical trials evaluating
                      theactivity of systemic therapies for adults with recurrent
                      meningiomas. The pooled progression-free survival at6-months
                      and 1-year (PFS-6 and PFS-1 year) values were calculated
                      using the random effects technique withI2 indices.Results.
                      The pooled PFS-6 and PFS-1 year rates for recurrent WHO
                      grade 1 meningiomas were $43.6\%$ $(95\%$ $CI:22.7-67.0\%,$
                      I2 = $80\%)$ and $21.7\%$ $(95\%$ CI: $6.2-53.9\%,$ I2 =
                      $76\%),$ and for grades 2-3 meningiomas, the PFS-6 was
                      $38.0\%(95\%$ CI: $28.3-48.8\%,$ I2 = $68\%).$ In the
                      targeted therapy group, PFS-6 and PFS-1 year rates stood at
                      $62.0\%$ (I2 = $58\%)and$ $49.0\%$ (I2 = $63\%)$ for grade
                      1, while for grades 2-3 tumors, the PFS-6 rates with
                      targeted therapy and immunotherapywere $42.1\%$ (I² =
                      $60\%)$ and $46.0\%$ (I² = $0\%),$ respectively. The
                      benchmarks were set at $67\%$ and $54\%$ for PFS-6and PFS-1
                      year for grade 1 tumors, and PFS-6 of $49\%$ for grades 2-3
                      tumors.Conclusions. Several studies have reported outcomes
                      in patients with recurrent meningiomas testing a variety
                      ofagents with modest, but variable and progressively
                      increasing activity. In this context, we recommend new
                      benchmarksfor future trials to define efficacy of future
                      investigational therapies.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1093/neuonc/noaf009},
      url          = {https://juser.fz-juelich.de/record/1052252},
}